Ken Fisher Fisher Asset Management
Ken Fisher is the founder and executive chairman of Fisher Investments, a global money management firm overseeing billions of dollars in assets. He gained early recognition for pioneering the use of the price-to-sales ratio in stock analysis and wrote the long-running “Portfolio Strategy” column in Forbes. Over the years, Fisher has authored numerous books on investing and wealth management, many of which have become bestsellers.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$907M |
| 2 |
Apple
AAPL
|
+$260M |
| 3 |
Microsoft
MSFT
|
+$223M |
| 4 |
Amazon
AMZN
|
+$173M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$160M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$471M |
| 2 |
NVO
Novo Nordisk
NVO
|
+$177M |
| 3 |
AZPN
ASPEN TECHNOLOGY INC
AZPN
|
+$160M |
| 4 |
Petrobras
PBR
|
+$153M |
| 5 |
Adobe
ADBE
|
+$146M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.79% |
| 2 | Healthcare | 12.41% |
| 3 | Financials | 9.98% |
| 4 | Consumer Discretionary | 9.11% |
| 5 | Communication Services | 6.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
iShares Expanded Tech-Software Sector ETF
IGV
$14B
| $7.52M | 0.01% |
139,500
+76,975
| +123% | +$4.52M |
|
352
DigitalOcean
DOCN
$14.8B
| $7.45M | 0.01% |
+180,086
| New | +$8.03M |
|
353
Vertex Pharmaceuticals
VRTX
$123B
| $7.4M | 0.01% |
26,253
+1,669
| +7% | +$447K |
|
354
FormFactor
FORM
$9.17B
| $7.38M | 0.01% |
190,532
-5,144
| -3% | -$198K |
|
|
B
355
DELISTED
Barnes Group Inc.
B
| $7.22M | 0.01% |
232,000
| – | – |
|
356
Atlantic Union Bankshares
AUB
$6.09B
| $7.09M | 0.01% |
209,000
| – | – |
|
357
First Interstate BancSystem
FIBK
$3.6B
| $7M | 0.01% |
183,560
+552
| +0.3% | +$19.7K |
|
358
United Rentals
URI
$71.9B
| $6.91M | ﹤0.01% |
28,428
-921
| -3% | -$271K |
|
|
MDC
359
DELISTED
M.D.C. Holdings, Inc.
MDC
| $6.87M | ﹤0.01% |
212,658
+36,037
| +20% | +$1.29M |
|
360
Neurocrine Biosciences
NBIX
$16.4B
| $6.87M | ﹤0.01% |
70,478
-4,178
| -6% | -$386K |
|
361
Snap-on
SNA
$21.5B
| $6.82M | ﹤0.01% |
34,586
-10,453
| -23% | -$2.23M |
|
362
Eversource Energy
ES
$27.1B
| $6.77M | ﹤0.01% |
80,198
-18,318
| -19% | -$1.63M |
|
363
CVS Health
CVS
$123B
| $6.69M | ﹤0.01% |
72,196
+4,416
| +7% | +$431K |
|
364
VanEck Semiconductor ETF
SMH
$72.2B
| $6.68M | ﹤0.01% |
65,602
+35,346
| +117% | +$4.1M |
|
365
Tetra Tech
TTEK
$8.89B
| $6.68M | ﹤0.01% |
244,575
+36,320
| +17% | +$996K |
|
366
Morningstar
MORN
$7.41B
| $6.67M | ﹤0.01% |
27,565
+6,753
| +32% | +$1.7M |
|
|
PCH
367
DELISTED
PotlatchDeltic
PCH
| $6.66M | ﹤0.01% |
150,710
+28,739
| +24% | +$1.48M |
|
368
Globe Life
GL
$14.3B
| $6.6M | ﹤0.01% |
67,752
+4,002
| +6% | +$392K |
|
369
Vanguard Total World Stock ETF
VT
$79.1B
| $6.48M | ﹤0.01% |
75,945
+13,462
| +22% | +$1.24M |
|
370
Associated Banc-Corp
ASB
$5.92B
| $6.45M | ﹤0.01% |
353,123
+123
| +0% | +$2.49K |
|
371
Acuity Brands
AYI
$10.7B
| $6.43M | ﹤0.01% |
41,744
+9,066
| +28% | +$1.54M |
|
372
Cooper Companies
COO
$14.5B
| $6.28M | ﹤0.01% |
80,236
-20,904
| -21% | -$1.85M |
|
373
ICU Medical
ICUI
$4.15B
| $6.25M | ﹤0.01% |
38,000
| – | – |
|
374
Weyerhaeuser
WY
$18.4B
| $6.12M | ﹤0.01% |
184,828
-43,035
| -19% | -$1.64M |
|
375
Southern Company
SO
$106B
| $6.11M | ﹤0.01% |
85,609
-80,850
| -49% | -$5.94M |
|
Similar funds
Ken Fisher's Q2 2022 Portfolio in Review
As of Q2 2022, Ken Fisher held 1,196 positions worth $141B, down 17% from $169B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Ken Fisher's Q2 2022 filing shows 110 new, 483 increased, 318 reduced and 131 closed positions. Its largest new stake was Woodside Energy: 6,156,348 shares worth $133M. The largest sale was Eli Lilly, an estimated $471M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 29% a quarter earlier, followed by Healthcare and Financials.
- Ken Fisher's largest Q2 2022 buy was Woodside Energy: 6,156,348 shares worth $133M.
- Ken Fisher added most to Johnson & Johnson in Q2 2022, an estimated $907M increase.
- Ken Fisher's biggest Q2 2022 reduction was Eli Lilly, cutting an estimated $471M.
- Ken Fisher fully exited ASPEN TECHNOLOGY INC in Q2 2022, selling an estimated $160M.
- Ken Fisher's ten largest holdings make up 30% of its $141B portfolio in Q2 2022.
- Ken Fisher opened 110 new positions and closed 131 in Q2 2022.
- Ken Fisher's portfolio value fell 17% quarter-over-quarter to $141B.
Based on Fisher Asset Management's 13F filing for Q2 2022, filed 9 Aug 2022.